A5038040018- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes and associated disorders
- Primary Care and Health Outcomes
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Obesity and Health Practices
- Obesity, Physical Activity, Diet
- Chronic Disease Management Strategies
- Health Policy Implementation Science
- Clinical practice guidelines implementation
- Indigenous Health, Education, and Rights
- Diet and metabolism studies
- Pharmaceutical Practices and Patient Outcomes
- Gestational Diabetes Research and Management
- Fatty Acid Research and Health
- Health Systems, Economic Evaluations, Quality of Life
- Food Security and Health in Diverse Populations
- Nutritional Studies and Diet
- Adipokines, Inflammation, and Metabolic Diseases
- Pharmacology and Obesity Treatment
- Diet, Metabolism, and Disease
Western University
2016-2025
BP (Canada)
2024
St Joseph's Health Care
2008-2024
University of Pretoria
2024
Sandwell & West Birmingham Hospitals NHS Trust
2024
University of Toronto
1991-2023
Sunnybrook Health Science Centre
2023
Health Sciences Centre
2023
Centre for Family Medicine
2012-2021
Office of Naval Research
2012-2020
OBJECTIVE To examine cross-sectional associations of serum vitamin D [25-hydroxyvitamin D, 25(OH)D] concentration with insulin resistance (IR) and β-cell dysfunction in 712 subjects at risk for type 2 diabetes. RESEARCH DESIGN AND METHODS Serum 25(OH)D was determined using a chemiluminescence immunoassay. Insulin sensitivity/resistance were measured the Matsuda sensitivity index oral glucose tolerance tests (ISOGTT) homeostasis model assessment HOMA-IR. β-Cell function both insulinogenic...
The long-term efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated over 104 weeks in patients aged 55-80 years with type diabetes mellitus (T2DM) inadequately controlled on stable antihyperglycaemic agent regimen.In this randomized, double-blind, phase III study, received canagliflozin 100 or 300 mg placebo once daily during 26-week core period (N = 714) 78-week extension (n 624). Efficacy endpoints at week included change from baseline glycated...
Recent research suggests that tumor necrosis factor-α (TNFα) may play an important role in obesity-associated insulin resistance and diabetes. We studied the relationship between TNFα anthropometric physiological variables associated with diabetes isolated Native Canadian population very high rates of type 2 mellitus (DM). A stratified random sample (n = 80) participants was selected from a population-based survey designed to determine prevalence DM its risk factors. Fasting blood samples...
Abstract Aims Insulin is generally withheld until people with Type 2 diabetes are unresponsive to other therapies. However, its potential advantages suggest that it could be added earlier achieve glycaemic goals; this possibility was tested in a clinical trial. Methods Consenting adults aged 18–80 years for at least 6 months, HbA 1c of 7.5–11%, and on 0, 1 or oral agents, were randomized one two therapeutic approaches 24 weeks: evening insulin glargine plus self‐titration by unit/day if the...
Hypoglycaemic events, particularly nocturnal, affect health-related quality of life (HRQoL) via acute symptoms, altered behaviour and fear future events. We examined the respective disutility associated with a single event daytime, severe non-severe hypoglycaemia.Representative samples were taken from Canada, Germany, Sweden, United States Kingdom. Individuals completed an internet-based questionnaire designed to quantify HRQoL different diabetes- and/or hypoglycaemia-related health states....
To examine the prospective associations of baseline vitamin D [25-hydroxyvitamin D; 25(OH)D] with insulin resistance (IR), β-cell function, and glucose homeostasis in subjects at risk for type 2 diabetes.We followed 489 subjects, aged 50 ± 10 years, 3 years. At follow-up, 75-g oral tolerance tests (OGTTs) were administered. IR was measured using Matsuda index (IS(OGTT)) model assessment (HOMA-IR), function determined both insulinogenic divided by HOMA-IR (IGI/IR) secretion sensitivity...
OBJECTIVE Emerging evidence suggests that peripheral neuropathy begins in the early stages of diabetes pathogenesis. Our objective was to describe prevalence and nerve dysfunction according glucose tolerance metabolic syndrome status examine how these conditions are associated with neurological changes individuals at risk for type 2 diabetes. RESEARCH DESIGN AND METHODS We studied 467 longitudinal PROMISE (Prospective Metabolism Islet Cell Evaluation) cohort. Peripheral defined by Michigan...
Abstract Aim To investigate the safety and efficacy of insulin degludec/liraglutide ( ID egLira), a novel combination product, as add‐on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy. Methods In this 26‐week, double‐blind trial, adults [HbA 1c 53–75 mmol/mol (7.0–9.0%)] were randomized to egLira n = 289) or placebo 146) pre‐trial ± metformin, titrating fasting glycaemic target 4.0–6.0 mmol/l. Treatment initiation was at 10 dose steps, maximum 50 steps (50...
Context: Emerging evidence suggests that 25-hydroxy vitamin D [25(OH)D] and PTH may play a role in the etiology of metabolic syndrome (MetS). However, to date is limited inconsistent, few studies have examined associations with nontraditional MetS components. Objective: The objective study was examine association its traditional components large multiethnic sample. Design, Setting, Participants: In this cross-sectional study, we 654 participants from London Toronto, Ontario, Canada, aged 30...
Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type diabetes mellitus (T2DM). The efficacy and safety canagliflozin were evaluated in T2DM <65 ≥65 years age. Pooled data from 4 randomised, placebo-controlled, 26-week, Phase 3 studies (N = 2,313) evaluating 100 300 mg analysed by age: (n 1,868; mean age, 52.8 years) or 445; 69.3 years). Efficacy evaluations included change baseline glycaemic parameters systolic blood pressure (BP),...
Objective Very few real-world studies have been conducted to assess the incidence of diabetes-related hypoglycemia. Moreover, there is a paucity that investigated hypoglycemia among people taking secretagogues as monotherapy or in combination with insulin. Accordingly, our research team developed and validated InHypo-DM Person Diabetes Mellitus Questionnaire (InHypo-DMPQ) aim capturing self-reported, symptomatic The questionnaire was administered online national sample Canadians (≥18 years...
Objectives To compare the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor developed to treat type diabetes mellitus (T2DM), in individuals younger than 75 those aged older. Design Randomized Phase 3 studies. Setting International study centers. Participants Adults with T2DM. Measurements Changes from baseline glycosylated hemoglobin (HbA 1c ), fasting plasma ( FPG blood pressure BP body weight were measured. Efficacy was evaluated using pooled data six...
The aim of this study was to investigate the impact hypoglycemia according severity and time onset on health-related quality life (HRQoL) in a Canadian population.Time trade-off (TTO) methodology used estimate health utilities associated with hypoglycemic events representative sample population. A global analysis conducted United Kingdom, Canada, Germany Sweden has been published. present focuses 3 populations: general, type 1 2 diabetes. Using web-based survey, participants (>18 years)...